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Abstract - BK virus (BKV) and JC virus (JCV) persist as latent infection in the kidneys. Reactivation of both viruses may 
be linked to immunodeficiency. The aims of this study were to determine the prevalence of BKV and JCV viruria and to 
evaluate the relationship between immunodeficiency and viruria in a cohort of HIV-infected patients. Urine samples from 
93 HIV-infected patients were collected and tested for the presence of BKV and JCV DNA by PCR. The overall preva-
lence of polyomavirus DNA in urine was 74.2%. BKV DNA was detected in 30.1% urine samples and JCV DNA in 23.7% 
samples. Both BKV and JCV DNA were detected in 20.4% samples. There was no association between BKV/JCV urinary 
shedding and the degree of immunosuppression measured by CD4+ cell count. However, taking into account the severity 
of disease resulting from reactivation of BKV and JCV, patients with HIV/polyomavirus co-infection should be kept under 
frequent and regular supervision.
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INTRODUCTION
BK virus (BKV) and JC virus (JCV) are worldwide-
distributed  polyomaviruses  in  the  human  popula-
tion.  Primary  infection  with  both  viruses,  which 
occurs  mainly  during  early  childhood,  is  usually 
asymptomatic or linked to mild respiratory disease 
(Goudsmit  et  al.,  1981).  After  primary  infection, 
both viruses persist as latent infection in the kidneys 
and upper part of the urinary tract (Chester et al., 
1983). 
Epidemiological  studies  have  shown  that  se-
roprevalence is very high for both viruses, ranging 
from 70 to 90% (Gardner et al., 1973; Padgett and 
Walker,  1973).  Seroconversion  for  BKV  occurs  in 
children aged 5 to 7, while JCV seroconversion usu-
ally occurs after the age of 10 (Knowels, 2006). The 
BKV antibody titer decreases throughout life, while 
antibodies against JCV remain stable and increase 
during life (Knowels et al., 2003; Jiang et al., 2009).
Asymptomatic shedding of BKV has been de-
scribed in 5% of healthy adults, while 20 to 30% of 
seropositive immunocompetent adults sporadically 
shed JCV in the urine (Doerries, 2001). Higher in-
cidence of reactivation is observed in immunocom-
promised  patients  (HIV-infected  patients,  cancer 
patients, transplant organ recipients, etc.) (Gardner 
et al., 1984; Dubois et al., 1996; Arthur et al., 1988). 
In recent years, several immunomodulatory drugs 
(monoclonal antibodies) used for the treatment of 610 DANIJELA KARALIĆ ET AL.
autoimmune diseases, as a side effect lead to increased 
reactivation of both viruses, especially JCV (Carson 
et al., 2009; Major, 2010). In immunocompromised 
individuals, the reactivation of human polyomavi-
rus can cause severe and life-threatening diseases. 
Reactivation of JCV results in lytic infection of oli-
godendrocytes in the brain and the development of 
progressive multifocal leukoencephalopathy (PML) 
(Jiang et al., 2009), while reactivation of BKV is as-
sociated with hemorrhagic cystitis, ureteral stenosis 
and polyomavirus induced nephropathy (Apperley 
et al., 1987; Gardner et al., 1971). 
Knowing the severity of diseases associated with 
the reactivation of human polyomaviruses in immu-
nocompromised individuals, the aims of this study 
were to determine the prevalence of BK and JC viru-
ria and critically evaluate the relationship between 
immunodeficiency and viruria in a cohort of HIV-
infected patients in Serbia. 
MATERIALS AND METHODS
Urine samples and subjects
Urine samples were collected from 93 non-selected 
consecutive HIV-infected patients who were under-
going regular follow-up at the Outpatient Unit of the 
Clinic of Infectious and Tropical Diseases, Clinical 
Center of Serbia. 
Single urine samples were collected from all in-
dividuals and stored at -70˚C until tested. Informed 
consent was obtained from each donor and the study 
was approved by the Ethics Committee of Faculty of 
Medicine, University of Belgrade No 29/VI-12.
DNA extraction and amplification of JCV VP1 and 
BKV VP1 regions
Ten milliliters of urine were centrifuged at 4 000g for 
10 min. The sediment was re-suspended in 5 ml of 
sterile phosphate-buffered saline (PBS) and recentri-
fuged. The supernatant was discarded and viral DNA 
was then extracted by using the QIAamp DNA Mini 
Kit (QIAGEN, Hilden, Germany), according to the 
manufacturer’s instructions.
Seminested-PCR was performed for amplifica-
tion of the 495-bp fragment within the VP1 coding 
region of the JCV genome. Primers P13 and M5 were 
applied for the first PCR round, and JLP1 and M5 for 
the second round (Table 1). PCR was carried out in 
a thermocycler Master Cycler Gradient (Eppendorf, 
Germany) following several steps: an initial dena-
turation at 95˚C for 5 min, followed by 40 cycles at 
95˚C for 30 s, 60˚C for 40 s, 72˚C for 60 s, and final 
extension at 72˚C for 10 min.
The BKV VP1 region was amplified by seminest-
ed-PCR where BKV1 and BKV2 were used as outer 
primers, and BKV3 and BKV2 as inner primers (Ta-
ble 1). Amplification of BKV VP1 was performed un-
der the same conditions as described above with the 
only difference in the annealing temperature, which 
was at 60˚C for 1 min.
Visualization  of  PCR  products  of  appropriate 
length was performed by electrophoresis in 2% agar-
ose gel stained with ethidium bromide.
Statistical analyses
The chi-squared test was used for statistical analy-
sis. Analysis was performed in SPSS v.20 (SPSS Inc., 
Chicago, IL) software. P<0.05 was considered signifi-
cant.
RESULTS
Ninety-three  HIV-infected  patients  (70  men,  23 
women) were enrolled in this study. The mean age 
was 44.24±10.63 years (range 23-70). The CD4+ T 
cell  count  was  determined  for  88/93  patients  and 
more than half of the patients (58%) presented CD4+ 
cell counts <200 cells/mm3.
The overall prevalence of polyomavirus DNA uri-
nary shedding was 69/93 (74.2%), while 25.8% urine 
samples were negative for both viruses. The overall 
prevalence of BKV and JCV was 50.5% and 44.1%, 
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(30.1%) urine samples and only JCV DNA was de-
tected in 22/93 (23.7%) samples. Both BKV and JCV 
DNA were detected in 19/93 (20.4%) samples. There 
was no statistically significant difference in detection 
rates of BKV DNA and JCV DNA among the patients 
participating in this study (χ2=0.517; p=0.472).
JCV DNA was more frequently detected among 
males than females and the detection rate of JCV 
DNA was significantly higher in men than in women 
(χ2=4.016; p =0.045) (Table 2). On the other hand, 
the detection rate of BKV DNA was similar between 
genders and the difference in detection rate of BKV 
DNA between genders did not reach statistical sig-
nificance (χ2=0.033; p=0.856) (Table 2). 
The number of positive samples for BKV and 
JCV were analyzed when all patients were grouped by 
Table 1. Primers used in this study for the amplification and sequencing of the JCV VP1 and BKV VP1 region
Primer Sequence(5’-3’) Nucleotide position Reference
JCV VP1 PCR
P13 ttccactacccaatctaaatgagg 1725-1748* Lafon et al. 1998
M5 gtttgtaaacatgccacagacatc 2263-2240* Lafon et al. 1998
JLP1 ctcatgtgggaggctgtgacct 1769-1790* Agostini et al. 1996
BKV VP1 PCR
BKV1 cgtgcaagtgccaaaactac 1626-1645** Zolana et al., 2011
BKV2 gaccctgcatgaaggttaag 1961-1942** Zolana et al., 2011
BKV3 gaagttaaaactggggtagta 1672-1694** Zolana et al., 2011
*Location of primers is relative to JCV Mad-1 numbering
**Location of primers is relative to BKV Dunlop numbering
Table 2. Prevalence of BKV and JCV by gender
No. of positive/total (%)
Female Male
P - value No. of positive/total (%) No. of positive/total (%)
BKV positive 47/93 (50.5%) 12/23 (52.2%) 35/70 (50%) NS
JCV positive 41/93 (44.1%)
6/23 (26.1%)
35/70 (50%) 0.045
NS - non significant
Table 3. Prevalence of JCV and BKV in HIV-infected patients grouped by age
Age  JCV positive (%) JCV negative (%) BKV positive (%) BKV negative (%)
21-30  3 (7.3) 8 (15.4) 5 (10.6) 6 (13)
31-40  11 (26.8) 16 (30.8) 13 (27.7) 14 (30.4)
41-50  13 (31.7) 17 (32.7) 16 (34) 14 (30.4)
51-60  10 (24.4) 9 (17.3) 11 (23.4) 8 (17.4)
61-70  4 (9.8) 2 (3.8) 2 (4.3)   4 (8.7)
P value NS NS
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age. There was no statistically significant difference 
in the proportion of positive samples between the 
age groups (χ2=5.051, p =0.654 for JCV; χ2=6.822, p 
=0.448 for BKV) (Table 3).
In  order  to  evaluate  the  relationship  between 
BKV/JCV  viruria  and  immunodeficiency,  HIV-in-
fected patients were divided into three groups ac-
cording to their CD4+ cell count: <200, 200-500, and 
>500 x 106 cells/L. The data showed no correlation 
between the frequency of BKV/JCV urinary excre-
tion and the degree of immunosuppression (meas-
ured by CD4+ cell count) (Tables 4 and 5).
DISCUSSION
Prolonged immunosuppression associated with HIV 
infection contributes to an increased reactivation of 
BKV and JCV (Nali et al., 2012). In the last decade, 
these viruses are gaining more and more attention 
from scientists because of the high mortality rate of 
diseases that occur due to their reactivation.     
In  the  present  study,  the  prevalence  of  BKV 
in HIV-infected patients who were shedding only 
BKV was 30.1%. However, the overall prevalence of 
BKV was higher when patients with the simultane-
ous excretion of both viruses is considered, reach-
ing 50.1%. This result is similar to those reported 
previously by Knowels et al. (1999) and Nali et al. 
(2012), although lower rates of less than 25% were 
detected by Sundsfjord et al. (1994). The reason for 
this may be due to the characteristics of the patients 
included in the studies, especially their immuno-
logical status (level of immunosuppression, CDC 
stage of disease etc.).  
The overall prevalence of JCV DNA in this study 
was as high as 44.1%. This frequency is similar to 
the detection rate of JCV DNA reported by Matos 
et al. (2010), although higher than most so-far pub-
lished data where JCV DNA was detected in the 
urine of 16 to 32% of HIV-infected patients (Sunds-
fjord et al., 1994; Knowles et al., 1999; Markowitz et 
al., 1993). 
Table 4. Prevalence of JCV viruria in HIV infected patients based on CD4+ cell count subdividing   
HIV infected patients
CD4+
(per mm3)
No. of JCV positive 
(%)
No. of JCV negative 
(%)
Total P - value
<200 24 (27.3) 27 (30.7) 51 (58) NS
201-500 13 (14.7) 19 (21.6) 32 (36.3) NS
500+ 2 (2.3) 3 (3.4) 5 (5.7) NS
Total 39 (44.3) 49 (55.7) 88 (100)
NS - non significant
Table 5. Prevalence of BKV viruria in HIV-infected patients based on CD4+ cell count subdividing
HIV infected patients
CD4+
(per mm3)
No. of BKV positive 
(%)
No. of BKV negative 
(%)
Total P - value
<200 29 (33) 22 (25) 51 (58) NS
201-500 13 (14.7) 19 (33) 32 (36.3) NS
500+ 2 (2.3) 3 (3.4) 5 (5.7) NS
Total 44 (50) 44 (50) 88 (100)
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This  study  showed  a  higher  prevalence  of  BK 
viruria than JC viruria in HIV-infected patients but 
no  statistically  significant  difference  was  reached. 
The results of our previous study (Karalic et al., 2012) 
involving  immunocompetent  Serbian  population 
showed that the prevalence of JCV urinary shedding 
is significantly higher than BKV shedding (29.2% v. 
4.6%). Furthermore, when the results of both stud-
ies are compared there was no statistically significant 
difference in JCV excretion rate between immuno-
competent  individuals  and  immunocompromised 
HIV-infected patients, indicating that immunosup-
pression has little effect on the reactivation of JCV 
and that probably some other factors are involved 
in its reactivation. On the other hand, a significantly 
higher rate of BK viruria in HIV-infected patients 
suggests that immunosuppression is one of the most 
important factors for the reactivation of BKV.
No association between BKV/JCV urinary shed-
ding and degree of immunosuppression measured 
by CD4+ cell count was found. This finding is similar 
to results from other studies (Behzad-Behbahani et 
al., 2004; Matos et al., 2010; Sundsfjord et al., 1994). 
On the other hand, studies done by Markowitz et al. 
(1993), Knowles et al. (1999) and Jin et al. (1995) 
found a correlation between BKV shedding and the 
degree of immunosuppression; the lower the CD4+ 
cell count the higher excretion rate of BKV was, but 
no association of JCV urinary excretion with immu-
nodeficiency was found. 
The majority of previously published studies (Ki-
tamura et al., 1990; Kmieciak et al., 2008; Matos et al., 
2010; Nali et al., 2012) found no association between 
gender  and  excretion  rate  of  BKV/JCV.  However, 
the results of this study and the study of Rossi et al. 
(2007) showed that men were more likely to excrete 
JCV in urine than women.
In the immunocompetent population, JCV uri-
nary excretion rate is age-related; in the older popu-
lation the excretion rate was higher (Kitamura et al., 
1990; Polo et al., 2004), but no association between 
urinary shedding of BKV with age was determined 
(Zhong et al., 2007; Kitamura et al., 1990). On the 
other hand, this study confirmed findings from other 
studies (Knowles et al., 1999; Nali et al., 2012) where 
no  statistically  significant  difference  was  observed 
between excretion rates of BKV/JCV and the age of 
patients in immunocompromised HIV-infected pa-
tients.
In conclusion, this study showed a high preva-
lence of BKV and JCV DNA in the urine of HIV-in-
fected patients. BK viruria was more prevalent than 
JC viruria. This study confirmed that immunosup-
pression is the most important factor for the high 
prevalence of BKV reactivation, while some addi-
tional factors are needed for the reactivation of JCV. 
The severity of disease resulting from reactivation 
of BKV and JCV in patients with HIV/polyomavi-
rus co-infection should be kept under more frequent 
and regular supervision.
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